Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17338702 | 0.83 | APLNR (0.39) | TDP1APLNRCA1CA2CA7 | |
| SCHEMBL759712 | 0.81 | APLNR (0.56) | TDP1APLNRCA1CA2CA7 | |
| SCHEMBL5672978 | 0.80 | TDP1 (0.40) | TDP1APLNRCA1CA2CA7 | |
| SCHEMBL240769 | 0.80 | CA1 (0.42) | TDP1APLNRCA1CA2CA7 | |
| SCHEMBL17570627 | 0.80 | TDP1 (0.44) | TDP1APLNRCA1CA2MAOA | |
| SCHEMBL5989055 | 0.79 | CA1 (0.38) | TDP1APLNRCA1CA2CA7 | |
| SCHEMBL27737493 | 0.79 | MAOA (0.40) | TDP1APLNRCA1CA2CA7 | |
| SCHEMBL28431384 | 0.79 | TDP1 (0.38) | TDP1APLNRCA1CA2CA7 | |
| SCHEMBL13625265 | 0.78 | APLNR (0.44) | TDP1APLNRCA1CA2CA7 | |
| SCHEMBL20578018 | 0.78 | MEN1 (0.42) | TDP1APLNRCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939974-B | Preparation method of aza-benzoazulene derivative | 中山大学 | 2023-10-20 | — | — | CN | claimed |
| CN-112939974-A | Preparation method of azabenzoazulene derivative | 中山大学 | 2021-06-11 | — | — | CN | claimed |
| EP-3991725-B1 | NOVEL ENTERO-ANTISEPTIC FOR THE TREATMENT OF GASTROINTENSTINAL INFECTIONS IN HUMANS | NINKOV DUSAN (HU) | 2026-01-28 | — | — | EP | disclosed |
| WO-2025056068-A1 | BICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海济煜医药科技有限公司 | 2025-03-20 | — | — | WO | disclosed |
| US-20240374551-A1 | ENTERO-ANTISEPTIC FOR THE TREATMENT OF GASTROINTESTINAL INFECTIONS IN HUMANS | NINKOV DUSAN (US) | 2024-11-14 | — | — | US | disclosed |
| CN-118164994-A | Camptothecin derivatives and antibody drug conjugates thereof | 石药集团巨石生物制药有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-112939974-B | Preparation method of aza-benzoazulene derivative | 中山大学 | 2023-10-20 | — | — | CN | disclosed |
| EP-3991725-A1 | NOVEL ENTERO-ANTISEPTIC FOR THE TREATMENT OF GASTROINTENSTINAL INFECTIONS IN HUMANS | Ninkov, Dusan (HU) | 2022-05-04 | — | — | EP | disclosed |
| CN-112939974-A | Preparation method of azabenzoazulene derivative | 中山大学 | 2021-06-11 | — | — | CN | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| CN-104080783-A | Pyrrole compounds | YAKULT HONSHA KK | 2014-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374551-A1 | ENTERO-ANTISEPTIC FOR THE TREATMENT OF GASTROINTESTINAL INFECTIONS IN HUMANS | VIP, SI, CEL | TDP1 4273/4885APLNR 2926/4885CA1 3567/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | TDP1 3690/4885APLNR 920/4885CA1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.